College of Osteopathic Medicine Faculty Articles

Title

Bone Marrow Somatic Mutation after Genotoxic Cancer Therapy

ISBN or ISSN

0140-6736

Publication Title

Lancet

Volume

343

Issue

8911

Publication Date / Copyright Date

6-1-1994

DOI Number

10.1016/S0140-6736(94)92619-0

Abstract

The glycophorin A (GPA) somatic mutation assay has been shown to act as cumulative biodosimeter of chemotherapy in pediatric patients, but to show no response to localized high-dose radiotherapy. These results are consistent with studies in adult populations treated with cyclophosphamide and doxorubicin or cisplatin, but inconsistent with results showing induction of somatic mutation at the GPA locus in patients treated with localized or implant radiation. The GPA assay directly measures in-vivo somatic mutation and segregation occurring by any of several molecular mechanisms implicated in oncogenesis. It has the advantage of integrating environmental and genetic factors when evaluating the long-term health effects of medical exposures. Ultimately, application of this and other intermediate biomarkers of carcinogenesis will permit individualized design and modification of therapeutic regimen and better prognostic assessment in all types of cancer.

Disciplines

Medical Specialties | Medicine and Health Sciences | Osteopathic Medicine and Osteopathy

This document is currently not available here.

Peer Reviewed

Find in your library

Share

COinS